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Abstract
Background: Over the last decade, multiple large randomized controlled trials have studied alternative transfusion
strategies in critically ill patients, demonstrating the safety of restrictive transfusion strategies. Due to the lack of
international guidelines specific for the intensive care unit (ICU), we hypothesized that a large heterogeneity in
transfusion practice in this patient population exists. The aims of this study were to describe the current transfusion
practices and identify the knowledge gaps.
Methods: An online, anonymous, worldwide survey among ICU physicians was performed evaluating red blood
cell, platelet and plasma transfusion practices. Furthermore, the presence of a hospital- or ICU-specific transfusion
guideline was asked. Only completed surveys were analysed.
Results: Nine hundred forty-seven respondents filled in the survey of which 725 could be analysed. Hospital
transfusion protocol available in their ICU was reported by 53% of the respondents. Only 29% of respondents used
an ICU-specific transfusion guideline. The reported haemoglobin (Hb) threshold for the general ICU population was
7 g/dL (7–7). The highest reported variation in transfusion threshold was in patients on extracorporeal membrane
oxygenation or with brain injury (8 g/dL (7.0–9.0)). Platelets were transfused at a median count of 20 × 109 cells/L
IQR (10–25) in asymptomatic patients, but at a higher count prior to invasive procedures (p < 0.001). In patients
with an international normalized ratio (INR) > 3, 43% and 57% of the respondents would consider plasma
transfusion without any upcoming procedures or prior to a planned invasive procedure, respectively. Finally,
doctors with base specialty in anaesthesiology transfused critically ill patients more liberally compared to internal
medicine physicians.
Conclusion: Red blood cell transfusion practice for the general ICU population is restrictive, while for different
subpopulations, higher Hb thresholds are applied. Furthermore, practice in plasma and platelet transfusion is
heterogeneous, and local transfusion guidelines are lacking in the majority of the ICUs.
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Introduction
As critically ill patients frequently develop anaemia,
thrombocytopenia or coagulopathy [1–3], transfusion of
blood components is a frequent intervention in the in-
tensive care unit (ICU). About 12.5% of all transfused
red cell concentrates (RCCs), 13% of all platelet concen-
trates (PC) and 30% of all plasma units in the hospital
are transfused in the ICU [4]. However, these products
are associated with life-threatening adverse events in-
cluding transfusion-related acute lung injury (TRALI),
transfusion-associated cardiac overload (TACO) and
transfusion-related immunomodulation (TRIM) [5–7].
Since the Transfusion Requirements in Critical Care
(TRICC) trial, 20 years ago, it has been increasingly rec-
ognized that a restrictive RCC transfusion strategy may
be as safe as a liberal strategy and even reduce patient
mortality in specific patient subpopulations [8]. Conse-
quently, ICU transfusion practice has shifted towards
more restrictive strategies. From 2002 to 2012, the inci-
dence of RCC transfusion in critically ill patients has
dropped from 37 [9] to 26% [1] during ICU admission.
This reduction coincided with the publication of mul-
tiple large international randomized controlled trials
(RCTs) showing the safety of a restrictive transfusion
strategy [8, 10, 11].
While multiple large RCTs have been performed to
compare liberal versus restrictive strategies in red blood
cell transfusions in ICUs, RCTs studying the optimal
transfusion strategies in critically ill patients for plasma
and platelets are limited or had a small sample size [12].
It is difficult to judge what “appropriate” transfusion
triggers are for these blood products. This uncertainty is
reflected in poor adherence to recommended best prac-
tices. It is estimated that hospital-wide 37% of transfused
plasma units and 33% of transfused platelets are admin-
istered outside the guideline recommendations [13–15].
Of note, there is no international ICU transfusion guide-
line. The aim of this survey was to evaluate the use of local
transfusion guidelines in the ICU and the applied transfu-
sion thresholds for RCC, platelet (PLT) and plasma trans-
fusion in ICU patients without an active haemorrhage.
Methods
Survey
An anonymous survey on transfusion practices in non-
bleeding patients was conducted among intensivists,
intensivist in training and non-intensivist specialists at-
tending in the intensive care medicine. This survey was
initiated by the Cardiovascular Dynamics Section and
endorsed by the European Society of Intensive Care
Medicine (ESICM). In addition, multiple national inten-
sive care societies distributed the survey to its members
by newsletters and/or promoted it on their website (see
Additional file 1 for contributors).
Study design
An online platform was used to set up the questionnaire
(SurveyMonkey, Portland, OR, USA). After designing,
the survey was tested by an international panel of inten-
sivists to optimize the validity and accuracy of the ques-
tionnaire. The survey included 40 questions, divided into
4 sections: respondent demographics, transfusion prac-
tice regarding red blood cells (15–17 questions), platelets
(5 questions) and plasma transfusions (8 questions, see
Additional file 1 for static version). Multiple clinically
relevant subpopulations (also non-bleeding) were ad-
dressed in each section. For red cell transfusion, first,
the preferred haemoglobin (Hb) threshold for the gen-
eral ICU population was asked, followed by the preferred
Hb level for each subpopulation. For platelet transfusion,
a distinction was made between transfusions prophylac-
tically and prior to different invasive procedures. For
plasma transfusions, a distinction was made between
prophylactic transfusion without a planned procedure
and prior to an invasive procedure in general.
Statistical analysis
Only completed surveys were analysed. Since some
questions were not applicable for all doctors, respon-
dents were allowed to leave specific questions about sub-
groups/specific interventions open. This missing data
was not imputed.
Descriptive statistics were used to characterize the re-
spondent demographics. Normally distributed and non-
normally distributed data were reported as mean (stand-
ard deviation) or as median (first quartile-third quartile),
respectively. Categorical data was presented as percent-
age. Participants were able to fill in Hb thresholds in g/
dL, g/L, or mmol/L, and all answers were converted to
g/dL for analysis.
Transfusion thresholds were not normally distributed;
therefore, the Kruskal-Wallis test was used to test
whether the transfusion thresholds differed significantly
in subpopulations or between interventions. As a post
hoc test, the Dunn test with Bonferroni correction was
used. In addition, transfusion thresholds were analysed
using the Wilcoxon sum rank test or Kruskal-Wallis test
to test the dependence of two grouping variables or
more than two grouping variables, respectively. Chi-
square test with Yates’s correction for continuity was
used for categorical variables. For comparing different
world regions, only the regions where at least ten re-
spondents were working were taken into account be-
cause they may not accurately represent the transfusion
practice across their region. All tests were two sided. A
p value < 0.05 was considered to be statistically signifi-
cant. Statistical tests were performed with R studio
(2018, 3.5.1, Vienna).
Bruin et al. Critical Care          (2019) 23:309 Page 2 of 8
Results
Demographics
The survey was open for 6months (June 2018 to November
2018). Of the 947 received surveys, 769 were complete; of
these, 44 were excluded because the respondents did not
fulfil the study inclusion criteria (i.e. non-physician or paedi-
atric ICU physician). The remaining 725 who completed the
surveys (representing 69 countries) were included in the
study. The majority of the participants practised ICU in Eur-
ope (76%) (Additional file 1: Figure S1). Background special-
ties were mainly anaesthesiology (62%) and internal
medicine (20%); other demographics are shown in Table 1.
Red cell transfusion
The median reported Hb threshold used in the general
ICU population was 7 g/dL (7.0–7.5). Higher Hb transfu-
sion thresholds were reported in patients with acute cor-
onary syndrome (ACS), septic shock, acute brain injury,
those receiving extracorporeal membrane oxygenation
(ECMO), with acute respiratory distress syndrome
(ARDS), age over 65 years and with prolonged weaning
(p < 0.001 for all patient populations, see Fig. 1). Thresh-
olds did not differ between oncological/haematologic pa-
tients and the general ICU population (p = 1). The
largest variation in transfusion thresholds was observed
in patients on ECMO and in patients with traumatic
brain injury. Respondents would transfuse these patient
populations at a Hb threshold of 8.0 g/dL (7.0–9.0). The
highest Hb threshold was reported for patients with
ACS median of 9.0 g/dL (8.0–9.7).
Following the transfusion of the first RCC, Hb levels
were routinely not re-evaluated before transfusing a sec-
ond unit. Of the respondents, 28% always re-evaluate the
Hb level while 16% never re-evaluate.
Transfusion triggers
The majority of the respondents used clinical markers
such as hypotension and tachycardia along with Hb
levels to guide the transfusion. Among the respondents,
only 13% never uses other physiological triggers in
addition to a Hb threshold. Of interest, 27% of the re-
spondents would always use other physiological triggers
(Fig. 2a). Tachycardia (66%), hypotension (55%) and lac-
tate levels > 2mmol/L (51%) were mentioned most often
(Fig. 2b), while significant ECG changes were ranked as
the most important physiological trigger.
Prevention of RCC transfusion
The use of iron or iron in combination with erythropoi-
etin (EPO) to improve erythropoiesis and prevent RCC
transfusion was reported by 41% and 17% of respondents,
respectively. EPO was reported by 12% of the respondents
as a monotherapy. A quarter of the respondents would
never use these pharmacological agents for this purpose.
Non-pharmacological blood conservation measures were
less common in the ICU. Closed loop blood sampling was
the most common intervention (23%), followed by
Table 1 Respondents demographics
Demographics No. of respondents (%)
Certification level
Intensivist 589 (81)
Resident, specialist in training 53 (7)
Specialist, non-intensivist practising ICU 73 (10)
Others 10 (1)
Primary medical specialty
Anaesthesiology 450 (62)
Cardiology 18 (2)
Internal medicine 144 (20)
Neurology 4 (1)
Pulmonology 25 (3)
Surgery 15 (2)
Others 67 (10)
Type of intensive care unit (ICU)
Medical ICU 63 (9)
Surgical ICU 536 (74)
Mixed ICU 110 (15)
Others 16 (2)
Number of ICU beds
< 10 209 (29)
10–15 206 (28)
16–20 115 (16)
> 20 193 (27)
Not specified 2 (0)
Annual number of patients treated in the ICU
< 500 178 (25)
501–1000 239 (33)
1001–1500 139 (19)
1501–2000 66 (9)
> 2000 98 (14)
Not specified 5 (1)
Type of institution
University hospital 326 (45)
University-affiliated hospital 146 (20)
Non-university public hospital 183 (25)
Private hospital 64 (9)
Others 6 (1)
Which unit do you use to measure haemoglobin?
g/dL 499 (69)
g/L 171 (24)
mmol/L 55 (8)
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microtube sampling (13%). Computerized decision sup-
port was used by only 2% of the respondents.
Platelet transfusion
In non-bleeding patients without a planned invasive
procedure, respondents would transfuse patients at a
platelet count of 20 × 109 cells/L (10–25). Platelet
concentrates were transfused at higher platelet
counts prior to an invasive procedure (p < 0.001). Re-
spondents would transfuse at a platelet count of
40 × 109 cells/L (20–50) prior to central venous cath-
eter (CVC) placement, 50 × 109 cells/L (50–75) prior
to tracheotomy, 50 × 109 cells/L (50–80) prior to
general surgery and 100 × 109 cells/L (70–100) prior
to neurosurgery (Fig. 3). When transfusing a PLT
concentrate, 18% of the respondents never re-
Fig. 1 Respondents were asked which Hb threshold they used for RCC transfusion in the general ICU population and different subpopulations.
Respondents used in the general population a Hb threshold of 7.0 g/dL (7.0–7.5). This is significantly lower (p < 0.001) compared to patients with
acute coronary syndrome (9.0 g/dL (8–9.7)), septic shock (7.5 g/dL (7.0–8.0)), acute brain injury (8.0 g/dL (7.0–9.0)), patients undergoing ECMO (8.0
(7.0–9.0) g/dL), issues of prolonged weaning (7.5 g/dL (7.0–8.0)), or patients with ARDS (7.5 g/dL (7.0–8.0)). No statistical differences were observed
between the general ICU population and patients older than 65 years and patients with (haematological) oncology (all three groups were
transfused at a Hb threshold of 7.0 g/dL (7.0–7.5))
Fig. 2 a, b The use of transfusion triggers in addition to a haemoglobin threshold
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evaluate the platelet count before transfusing a sec-
ond unit.
Coagulopathy
The majority (87%) of the respondents transfuse their
patients with fresh frozen plasma; only 9.5% reported to
use pooled plasma to correct coagulopathy.
In non-bleeding patients who will not undergo an inva-
sive procedure, an international normalized ratio (INR) >
3 is infrequently corrected. Only 7% would always correct
a prolonged INR (Fig. 4a.). Vitamin K is the most com-
monly mentioned therapeutic agent to correct the INR in
these patients (85%), followed by plasma (43%) and pro-
thrombin complex (35%) (Fig. 4b).
More physicians would correct an INR > 3 prior to
an invasive procedure compared to patients who are
not undergoing an invasive procedure (p < 0.0001).
Among the respondents, 31% would always correct a
prolonged INR in this setting (Fig. 4a). Also, prior to
an invasive procedure, the majority (70%) of the re-
spondents would use vitamin K as a therapeutic op-
tion, followed by prothrombin complex (58%) and
plasma (57%) (Fig. 4c).
To diagnose coagulopathy, INR/prothrombin time
(99%), activated partial thromboplastin time (APTT,
97%) and fibrinogen level (94%) are widely available
tests in the ICU. Viscoelastic tests are less common;
only in the minority of the hospitals rotational
Fig. 3 Prophylactic platelet thresholds without any planned invasive procedure and prior to different procedures
Fig. 4 More respondents would correct a vitamin K-induced INR > 3 prior to an invasive procedure than in the absence of a procedure (a). Both
in the absence of an invasive procedure (b) and prior to an invasive procedure (c), the majority would correct this with vitamin K
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thromboelastometry (ROTEM, 31%) or thromboelasto-
graphy (TEG, 18%) is available as a diagnostic tool.
Guideline
Among the respondents, 29% have an ICU-specific and
53% a (not ICU specific) transfusion guideline in their
ICU. The availability of a guideline has a limited effect
on the transfusion practice. Only for the general ICU
population the presence of a (not ICU) specific transfu-
sion guideline was associated with a lower transfusion
threshold (p = 0.028, Additional file 1: Table S3). For
other ICU subpopulations, this association with RCC
transfusion practice was not present (Additional file 1:
Table S2 and S3). Also, for platelet and plasma transfu-
sion, no association was found between the presence of
a guideline and transfusion practice (Additional file 1:
Table S5 and S6).
Background specialty
To investigate whether the base specialty influences
transfusion practices, only the group anaesthesiology
(69% of the respondents) and internal medicine (20% of
the respondents) were sufficiently present to perform an
additional testing. For RCC, PC and plasma transfusion,
an association was found between the base specialty and
transfusion practice. Overall, the base specialty in anaes-
thesiology was associated with a more liberal transfusion
practice compared to internal medicine. With the excep-
tion of patients with ACS and patients on ECMO, physi-
cians with the base specialty in anaesthesiology said to
transfuse all subpopulations at significantly higher Hb
thresholds. Furthermore, anaesthesiologists more often
report the use of physiological triggers in addition to Hb
levels in their decision to transfuse than internal medicine
physicians (p = 0.02, see Additional file 1: Table S4). Also,
thrombocytopenic patients are transfused at higher plate-
let counts prior to CVC placement (p = 0.002) and prior
to tracheotomy (p = 0.007, Additional file 1: Table S7)
when treated by a physician with the base specialty in an-
aesthesiology. For plasma transfusion, only in prophylactic
transfusions a different practice was observed between
these two base specialties. Physicians with a base specialty
in anaesthesiology transfuse plasma prophylactically more
frequently (Additional file 1: Figure S3).
Regional differences
In all world regions, a median Hb threshold of 7 g/dL
(7.7) was reported for the general ICU population. For
different subpopulations, a greater variety was reported,
especially in patients with ACS and traumatic brain
injury and patients receiving ECMO (Additional file 1:
Figure S2). In platelet transfusion, some alignment exists
for prophylactic platelet transfusion with a median ap-
plied platelet count prophylactically between 15 and
20 × 109 cells/L for all world regions. However, prior to
an invasive procedure, more heterogeneity exists
(Additional file 1: Figure S4). Prior to general surgery,
the largest differences between the regions were ob-
served; in half of the regions, the mean of the applied
platelet threshold was 50 × 109 cells/L while in Southern
Asia and Southeastern Asia, a median platelet count of
72.5 and 100 × 109 cells/L was applied, respectively.
Lastly, also plasma transfusion practices differed between
world regions (Additional file 1: Figure S5). In Southern
Europe, only 17% would never correct a vitamin K-
induced INR > 3 in the absence of an invasive procedure,
whereas in Southeastern Asia, 50% would never correct
this INR.
Discussion
This is the largest survey on transfusion practice in non-
bleeding critically ill patients among ICU physicians to
date. The main findings of this study are (1) a high Hb
threshold variation between ICU subpopulations; (2) the
platelet transfusion threshold prior to invasive proce-
dures differs greatly between and within the procedures;
(3) plasma is considered by a large number of physicians
in non-bleeding patients even in the absence of an inva-
sive procedure; (4) base specialty of physicians is associ-
ated with variation in transfusion practices; and (5)
worldwide, institutions lack local ICU-specific transfu-
sion guidelines.
The reported Hb threshold for the general ICU popu-
lation in this survey is in line with the finding of the
TRICC study, which demonstrated the safety of a re-
strictive transfusion strategy in the ICU population [8].
However, when looking at different patient subpopula-
tions, a greater variety of applied Hb thresholds was
found. For the septic patients, respondents reported a
significantly higher Hb threshold compared to the gen-
eral population, which deviates from current evidence
supporting a restrictive transfusion strategy also in septic
patients [11]. For patients with ACS, the higher pre-
ferred Hb threshold of 9 g/dL (8–9.6) is in accordance
with the transfusion guideline from the National Insti-
tute for Health and Care Excellence (NICE, 2018), in
which a Hb threshold (8–10 g/dL) for patients with
symptomatic coronary disease is advised. Also, patients
with traumatic brain injury were transfused at higher Hb
thresholds since these patients may be more sensitive to
anaemia-induced cerebral hypoxia. However, evidence to
justify this more liberal transfusion practice is limited.
Multiple large RCTs are currently studying whether
these patients benefit from a liberal transfusion strategy
(ClinicalTrials.gov, NCT02968654 and NCT02981407).
This survey also showed a high variety of preferred Hb
thresholds for patients with ARDS and patients on
ECMO. Since the evidence for these subpopulations is
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limited, it is expected to observe a high heterogeneity in
transfusion practice. For ARDS patients, it is hypothe-
sized that the hypoxaemia should be compensated by in-
creasing the oxygen-carrying capacity of the circulating
blood by transfusing at higher Hb thresholds. However,
there is no solid evidence to support this practice, and
the downside of allogenic blood transfusion is not taken
into account in this reasoning.
The applied platelet threshold differed between pa-
tients with and without an upcoming invasive procedure.
The majority of the respondents (72%) would transfuse
non-bleeding critically ill patients at a platelet count of
≤ 20 × 109 cells/L. The potential harm of platelet transfu-
sion is supported by two recent RCTs, in which it was
shown that prophylactic platelet transfusion might be
particularly harmful in neonates [16] and in patients
with a cerebrovascular accident [17]. These studies can-
not be directly translated to the non-bleeding critically
ill adult patients, but they do show that platelet transfu-
sion is not an intervention without a risk. Prior to inva-
sive procedures, physicians transfuse platelets at higher
platelet counts, while the evidence for this is limited. A
meta-analysis has shown that complications prior to
CVC placement in patients with coagulopathy, including
thrombocytopenia and prolonged INR and APTT, are
rare [18]. Thus, the need for any platelet transfusion
prior to this procedure is questionable. A large RCT
studying the need for platelet transfusion prior to CVC
placement in severely thrombocytopenic patients is now
recruiting [19].
Multiple RCTs have failed to demonstrate beneficial
effects of prophylactic plasma transfusion prior to an in-
vasive procedure in critically ill patients with a pro-
longed INR [12, 20, 21]. The finding of this survey that
57% and 43% of physicians would consider transfusing
plasma to correct the prolonged INR in patients who
used vitamin K antagonists prior to an invasive proced-
ure or without a planned invasive procedure, respect-
ively, is striking in the absence of evidence for this
practice.
To our knowledge, the influence of base specialty of
intensivists on transfusion practice has not been studied
before. Our survey showed that doctors with a base spe-
cialty in anaesthesiology transfuse more liberally than
those with internal medicine as a base specialty. It might
be that doctors with an internal medicine background
are more aware of the harmful side effects of blood
products; alternatively, anaesthesiologists may tend to
treat patients at a higher risk of bleeding, and these
practices spill over into the ICU.
The strength of this survey is the large number of re-
spondents. However, both the anonymous character of
this survey and the origin of the respondents might have
introduced a selection bias and limits therefore the
worldwide generalizability of our findings. Theoretically,
it is possible that multiple respondents are employed in
the same hospital; however, also within hospitals hetero-
geneity in transfusion practice may exist. Furthermore,
the number of respondents who did receive this survey
but did not fill it in is unknown. We cannot exclude that
non-responders transfuse differently than the responders
of this survey. It may be possible that physicians with
more interest in transfusion practice and thus with more
awareness of the possible side effects of transfusion are
over presented in this survey. In addition, due to the
study design, it was not appropriate to perform multivar-
iable analysis. As a result, it was not possible to exclude
the presence of confounding variables on the observed
significant associations. And finally, as with any clinical
practice survey, the reported transfusion practices might
differ from actual transfusion practices. Ideally, these re-
sults are confirmed in a prospective cohort study.
Conclusion
In conclusion, in the general non-bleeding ICU popula-
tion, the reported RCC transfusion practice was rather
restrictive; however, in certain subpopulations including
the critically ill with septic shock, higher applied Hb
thresholds were reported, which deviates from the
current evidence. For other subpopulations such as pa-
tients with ARDS and patients on ECMO, well-powered
RCTs are needed. In addition, optimal platelet thresh-
olds are currently controversial and more awareness is
necessary for the correct indications of plasma transfu-
sion in non-bleeding patients. Finally, a local transfusion
guideline for critically ill patients is lacking in the major-
ity of ICUs worldwide.
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